Main Metabolic Pathways of TAK-802, a Novel Drug Candidate for Voiding Dysfunction, in Humans: The Involvement of Carbonyl Reduction by 11β-hydroxysteroid Dehydrogenase 1

Abstract

To investigate species differences in the metabolism of TAK-802, in vitro and in vivo metabolic profiles were compared between humans and animals. TAK-802 was mainly metabolized to M-I, M-II, M-III and M-IV in human and animal liver microsomes. Especially the M-IV formation in humans was greater than that in animals. Likewise, M-IV was detected to a lower extent in the plasma and excreta of animals administered with TAK-802, whereas the AUC_0–48 h of M-IV was approximately five-fold higher than that of TAK-802 in human plasma. These results indicate that the in vitro metabolic profile reflects the in vivo condition. Thus, to identify the metabolic pathway of TAK-802 in humans, the responsible enzyme to form M-IV was elucidated in vitro. Since M-IV is a reductive metabolite formed in microsomes, the possibility of involvement of 11β-hydroxysteroid dehydrogenase (11β-HSD), a carbonyl reductase located in microsomes, was first investigated. Consequently, M-IV formation was confirmed by incubation with human 11β-HSD1-expressing microsomes and was concentration-dependently inhibited by glycyrrhetinic acid, an inhibitor for 11β-HSD enzymes, indicating the involvement of 11β-HSD1 in the M-IV formation. In contrast, little M-IV formation was observed using rat 11β-HSD1, suggesting species differences between humans and rats. In addition, M-II was formed via M-IV, not via M-I and the CYP identification studies revealed that both M-I formation from TAK-802 and M-II formation from M-IV were mainly catalyzed by CYP3A4. In conclusion, 11β-HSD1 and CYP3A4 are principally responsible for the metabolism of TAK-802 in humans and 11β-HSD1 may be responsible for the observed species difference.

Key words

TAK-802 - 11β-hydroxysteroid ­dehydrogenase (11β-HSD) - CYP - metabolism - species difference

• References

• 1 Ishichi Y, Sasaki M, Setoh M et al. Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]propanoyl}-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds. Bioorg Med Chem 2005; 13: 1901-1911
• 2 Nagabukuro H, Okanishi S, Doi T. Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs. Eur J Pharmacol 2004; 494: 225-232
• 3 Hashimoto T, Nagabukuro H, Doi T. Effects of the selective acetylcholinesterase inhibitor TAK-802 on the voiding behavior and bladder mass increase in rats with partial bladder outlet obstruction. J Urol 2005; 174: 1137-1141
• 4 Nagabukuro H, Okanishi S, Imai S et al. Effects of TAK-802, a novel acetylcholinesterase inhibitor, on distension-induced rhythmic bladder contractions in rats and guinea pigs. Eur J Pharmacol 2004; 485: 299-305
• 5 Kakehi M, Tagawa Y, Kondo T et al. Disposition of the new potent acetylcholinesterase inhibitor 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidiny]-1-oxopropyl]-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) in rats, dogs and monkeys. Drug Res 2013; 63: 293-299
• 6 Rosemond MJ, Walsh JS. Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev 2004; 36: 335-361
• 7 Skarydová L, Wsól V. Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily. Drug Metab Rev 2012; 44: 173-191
• 8 Oppermann UC, Maser E. Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 2000; 144: 71-81
• 9 Forrest GL, Gonzalez B. Carbonyl reductase. Chem Biol Interact 2000; 129: 21-40
• 10 Rosemond St MJ, John-Williams L, Yamaguchi T et al. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact 2004; 147: 129-139
• 11 Oppermann UC, Filling C, Jörnvall H. Forms and functions of human SDR enzymes. Chem Biol Interact 2001; 130-132: 699-705
• 12 Odermatt A, Nashev LG. The glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations. J Steroid Biochem Mol Biol 2010; 119: 1-13
• 13 Maser E. Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases. Biochem Pharmacol 1995; 49: 421-440
• 14 Maser E, Friebertshäuser J, Völker B. Purification, characterization and NNK carbonyl reductase activities of 11β-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem Biol Interact 2003; 143-144: 435-448
• 15 Sawada H, Hara A, Nakayama T et al. Comparative studies on distribution and properties of carbonyl reductase in mammalian tissues. Prog Clin Biol Res 1982; 114: 275-289
• 16 Matsuura K, Bunai Y, Ohya I et al. Ultrastructural localization of carbonyl reductase in mouse lung. Histochem J 1994; 26: 311-316
• 17 Nakanishi M, Deyashiki Y, Ohshima K et al. Cloning, expression and tissue distribution of mouse tetrameric carbonyl reductase. Identity with an adipocyte 27-kDa protein. Eur J Biochem 1995; 228: 381-387
• 18 Arampatzis S, Kadereit B, Schuster D et al. Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol 2005; 35: 89-101
• 19 Meyer A, Vuorinen A, Zielinska AE et al. Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1. Drug Metab Dispos 2013; 41: 1671-1678
• 20 Meyer A, Vuorinen A, Zielinska AE et al. Carbonyl reduction of triadimefon by human and rodent 11β-hydroxysteroid dehydrogenase 1. Biochem Pharmacol 2013; 85: 1370-1378